Immunosuppression followed by hematopoietic stem cell transplant has shown potent, long-lasting efficacy for relapsing multiple sclerosis in early studies. Now comes a six-year phase 3 trial.
Powered exoskeletons and other emerging technologies for MS rehab are the focus of the latest episode in our peer-to-peer Neuro Pathways podcast.
We’ve been collecting objective, quantitative outcomes at scale among populations with multiple sclerosis and Parkinson disease to unleash the potential of data-guided care. Here are some promising status reports.
Positive findings from the large SUNBEAM and RADIANCE trials make an early 2020 FDA approval look likely. How will ozanimod stack up against the two currently available S1P receptor modulators?
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A slew of new disease-modifying therapies in the 17 years since the last guideline prompted the update. A co-author of the new document shares takeaways.
We’re launching a study to assess the feasibility, safety and preliminary efficacy of this rehabilitative technology for a potential new application.
For some patients struggling with MS symptoms, suicide may seem like the last bit of control they have over their body. Our expert shares advice on suicide red flags specific to this patient population.
A new study suggests a model of gait training may be applicable to multiple sclerosis rehabilitation clinics with virtual reality systems of various levels of sophistication.
Findings from a large real-world multiple sclerosis dataset argue for continued use of brain and thalamic volume as clinical trial outcomes — and further work to apply them in clinical practice.
Use of highly effective disease-modifying therapies at leading multiple sclerosis centers hasn’t increased much over the past dozen years, an observational study reveals.